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Abstract: Age-related macular degeneration (AMD) – despite advances in prevention and 
medical treatment options – remains prevalent among older adults, often resulting in functional 
losses that negatively affect the mental health of older adults. In particular, the prevalence of both 
anxiety and depression in patients with AMD is high. Along with medical treatment options, 
low vision rehabilitation and AMD-specific behavioral and self-management programs have 
been developed and have demonstrated effectiveness in improving the mental health of AMD 
patients. This article reviews the prevalence of anxiety and depression in patients with advanced 
AMD, discusses potential mechanisms accounting for the development of depression and anxiety 
in AMD patients, presents the state-of the-art of available interventions for addressing anxiety 
and depression in AMD patients, and delineates recommendations for eye care professionals 
regarding how to screen for these two prevalent mental health problems and how to facilitate 
appropriate treatment for patients with AMD.
Keywords: age-related macular degeneration, vision impairment, depression, anxiety, vision 
rehabilitation, behavioral and self-management interventions
Introduction
Age-related macular degeneration (AMD) is a common cause of vision impairment 
and blindness1 affecting approximately 9% of the global population. It is most preva-
lent among individuals with European ancestry.2 Approximately 0.4% of the general 
population has late or advanced AMD with the prevalence of advanced AMD rising to 
8% among those 75 years of age and older.3 While the prevalence of all types of AMD 
has somewhat declined over the past decade, due to enhanced medical prevention and 
treatment options,4 the number of people with all types of AMD is expected to increase 
due to the rapid and consistent growth of the aging population. Recent projections 
estimate that worldwide the number of individuals with AMD will reach 196 million 
in 2020 and 288 million in 2040.2
There are two major types of AMD: one is the atrophic or non-exudative AMD, 
which progresses slowly and accounts for 80%–90% of AMD cases. The other type 
is the neovascular or exudative AMD which affects 10%–20% of patients but pro-
gresses rapidly, accounting for 80%–90% of cases with severe vision loss.5,6 Research 
has shown that a combination of antioxidant vitamins and mineral supplementation 
reduces the risk of developing advanced AMD in patients with intermediate atrophic 
AMD.7 Furthermore, anti-VEGF treatment was found to be effective in the clinical 
management of neovascular AMD.8,9
The most common negative consequence of the vision impairment caused by AMD 
is increased functional disability,10–12 which puts AMD patients at increased risk for 
mental health problems such as high levels of clinical depression and anxiety.13–15 It was 
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the hope that with the advent of effective treatment options 
for AMD that functional disability and the risk for mental 
health problems could be reduced. However, while most 
patients with neovascular AMD can achieve positive treat-
ment outcomes from anti-VEGF injections, there are approxi-
mately 10% whose treatment outcomes are non-optimal 
and fall below their expectations and are, therefore, still at 
increased risk for depression.13 Hence, current advances in 
treatment options cannot eliminate the risk for mental health 
problems in individuals with advanced AMD.
Therefore, this article provides an overview of the preva-
lence of anxiety and depression in patients with advanced 
AMD, discusses potential mechanisms that account for the 
development of depression and anxiety in patients with 
AMD, presents the state-of the-art of available interventions 
for addressing anxiety and depression in patients with AMD, 
and proposes recommendations for eye care professionals 
regarding how to screen for these two prevalent mental 
health problems and how to facilitate appropriate treatment 
for patients with AMD.
Prevalence of depression and 
anxiety in patients with AMD
Depression and anxiety are common in older adults,16 and 
even more common in older adults with visual impairment. 
Clinically significant subthreshold symptoms of depression 
have been found in approximately one-third of visually 
impaired older adults, which is approximately twice as 
high as the lifetime prevalence rates in the normally sighted 
general older population,13,15,17 where depressive symptoms 
affect roughly 15%.18,19 The prevalence of major depressive 
disorder based on the Diagnostic and Statistical Manual of 
Mental Disorders, 4th edition (DSM-IV) criteria in visually 
impaired samples aged $60 years ranges from approximately 
5% to 7%,15,17 while in community studies prevalence rates 
of just under 2% are reported.18,19
Among older adults with visual impairment, those with 
AMD seem to be particularly at risk for depression compared to 
those with other eye diseases.10,20 Popescu et al21 compared 
rates of depression in older adults with AMD, glaucoma, 
and Fuchs corneal dystrophy and found the highest rate of 
39% in the AMD group. When treatment outcomes fall below 
expectations, rates of depression are high even among those 
AMD patients who received VEGF treatment.10
Reports on anxiety are more variable. A recent study of 
615 visually impaired individuals aged 60 years and over 
(55.3% with AMD) showed that 15.6% had subthreshold 
symptoms of anxiety, compared to 11% in normally sighted 
peers.17 Over 7% (7.5%) of visually impaired persons were 
diagnosed with an anxiety disorder according to the DSM-IV, 
compared to 3.2% in the normally sighted. Agoraphobia 
(4.2%) and social phobia (2.4%) were particularly prevalent 
among those with visual impairment. Thus, as the authors 
conclude, visually impaired older adults are more prone to 
develop anxiety disorders related to specific places or social 
situations such as being on a bus or eating at a restaurant.
Among patients with AMD, prevalence estimates range 
between 9.6% and 30% for anxiety.22 However, case-control 
studies found that people with AMD were not more likely 
to experience symptoms of anxiety compared to those 
without AMD.22 Likewise, in a community-based sample 
of 662 individuals aged over 70 years, anxiety was signifi-
cantly associated with self-reported cataract, but not with 
AMD.20 Taken together, significant numbers of older adults 
with AMD experience depression and anxiety; thus, both 
constitute major public health problems in this population. 
However, symptoms of depression seem to be more prevalent 
than symptoms of anxiety and appear to be more prevalent 
among older adults with visual impairments compared to 
other adult populations. Nevertheless, there is evidence that 
specific anxiety disorders are particularly prevalent in visu-
ally impaired older adults, requiring specific interventions.
Potential mechanisms for the 
development of depression and 
anxiety in AMD
Four potential mechanisms for the development of depres-
sion and anxiety among patients with vision loss have been 
suggested. First, a strong relationship exists between loss 
of functional capacity and depression symptoms.13–15 Initial 
responses to the loss of functioning and valued activities 
may primarily consist of distress and frustration, and in some 
cases, a diagnosable adjustment disorder. A vicious cycle 
develops for the patient when the distress around these losses 
precipitates depression symptoms. The decreased motivation 
associated with these depressive symptoms leads to less 
engagement with valued activities, which, in turn further 
exacerbates the symptoms, and may exacerbate subthreshold 
or minor depression to major depressive disorder.
The second mechanism is a basic deficit in problem solv-
ing skills. Most AMD patients are 60 years and older, and 
have developed a well-tested repertoire of skills to approach 
common problems in life. Vision loss, however, is a novel 
problem for which such skills have not been developed and 
existing skills may not be sufficient to address this problem. 
Thus, approaches that emphasize actively approaching, 
developing, and applying problem solving skills have been 
found successful in reducing existing depression symptoms 
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for a variety of populations,23 including older, primary 
care patients with depression24 and depressed patients with 
comorbid executive functioning.25 In addition, problem 
solving treatment (PST) approaches can be effective in 
preventing depression symptoms among older patients with 
vision loss.26 These studies rely on teaching participants a 
systematic problem solving technique with which to remove 
barriers to activity engagement and increase pleasurable 
activities. Third, based on the life-span theory of control,27 
some authors suggest that different control strategies may 
need to be enacted at different stages of AMD.12,23 This 
theory proposes that it is of evolutionary advantage for 
individuals to use a variety of strategies to maximize control 
over their life and environment. These “control strategies” 
may be classified as primary – aimed at actively changing the 
external environment – or secondary – adapting one’s atti-
tudes to better match losses in active control (eg, goal adjust-
ment). The theory further suggests that both primary and 
secondary control can be either selective or compensatory. 
Thus, selective primary control, means that the older adult 
invests his or her energy, time, and effort in selected high 
priority goals (such as putting in additional effort to being 
able to read), whereas selective secondary control describes 
when motivational resources, such as goal commitment are 
used selectively (such as giving up one’s preference for 
reading for a less preferred, but feasible option: books on 
tape). Compensatory primary control describes a strategy 
in which the individual bolsters behavioral and emotional 
resources by external means (obtaining visual aids to help 
with reading), whereas compensatory secondary control 
involves “disengaging from the unattainable goal through 
self-protective strategies”,28 such as reducing the importance 
of reading for one’s well-being and seeking other sources of 
information. In the context of vision loss, primary control 
strategies that involve putting in more effort to harness 
internal resources and using low vision devices to maintain 
functioning are most useful early in the disease process. With 
declining vision and loss of everyday functioning it may 
be more useful to refocus one’s energy on realistic rather 
than futile goal pursuits (eg, finding non-visual sources of 
information). This helps preserve a sense of self and con-
tributes to the preservation of psychological health, because 
it reduces the frustration of feeling inadequate. In contrast, 
when inappropriate control strategies are used, the risk for 
distress is elevated.
Finally, recent work suggests that AMD is particularly 
difficult for individuals to cope with because it involves a 
poor future outlook: either sudden, unpredictable losses in 
visual field or visual acuity (for exudative AMD), or gradual 
and untreatable vision loss over decades (for dry AMD).5,6 
Dreading these future changes contributes to anxiety and 
feelings of hopelessness. Although the specific type and 
level of vision loss is difficult to predict in AMD, a gradual 
loss of certain abilities can be anticipated both as a result of 
AMD and aging in general. Many older adults, for example, 
must make decisions about whether to remain living at home 
or move into a more supportive environment. Sörensen et 
al have proposed an approach to preventing these psycho-
logical sequelae to vision loss by adapting problem solving 
therapy to include preparing for potential future needs and 
making plans for future loss of function.29 This preven-
tive problem solving training combines vision loss group 
education with in-home training. The education addresses 
AMD characteristics, etiology, and progression in lay 
terms, presents potential in-home adaptations to low vision, 
explains orientation and mobility training concepts, and 
probes potential emotional reactions to vision loss. The 
in-home training starts with traditional problem solving 
approaches and then applies these techniques to “areas of 
future concern”. Participants generate and/or are shown a 
list of potential future problems and work through how they 
can prepare for these. Preliminary results (not yet published 
or peer reviewed) in a randomized clinical trial suggest that 
depression symptoms are reduced post-preventive problem 
solving training for women in the treatment vs control group 
and for men at 6-month follow-up.30
Interventions designed to address 
depression and anxiety in AMD 
patients
Although research has consistently demonstrated that there is 
a high prevalence of depression in older people with impaired 
vision31–36 and that depression is most likely to develop in 
those who experience activity limitations (such as reduced 
participation in social activities and leisure pursuits),37,38 
depression in visually impaired persons, is under-diagnosed 
and treated.33,36,39,40 This is concerning because AMD is asso-
ciated with diminished quality of life, accelerated functional 
decline, and costly sequelae such as falls and nursing home 
placement.41 Depression may exacerbate these risks. Until 
we develop standardized and effective protocols for detecting 
and managing depression in this high risk population, a large 
proportion of patients with AMD will be at risk of potentially 
preventable consequences.41
Low vision rehabilitation approaches
Current treatment for AMD consists of medical treat-
ment (for neovascular AMD), vitamin therapy, and low 
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vision rehabilitation. For many patients, however, medical 
treatment is either not indicated (eg, anti-VEGF treatment 
is not effective for dry AMD), or when it is, many patients 
continue to experience psychological distress.13 Low vision 
rehabilitation aims to reduce vision-related disability by 
maximizing residual vision through training in the use of 
optical and assistive devices, orientation and mobility skills, 
and general compensatory strategies. But is low vision reha-
bilitation a reasonable treatment for depression? To the extent 
that depression in AMD results from activity restrictions, and 
that low vision rehabilitation fosters activity re-engagement, 
low vision rehabilitation might have an “antidepressant” 
effect. It may even ward off feelings of anxiety. From a cost 
perspective, it is worth considering whether existing treat-
ment modalities, such as low vision rehabilitation, ameliorate 
mental health problems. In the case of depression, some 
studies show improvement in depression following standard 
low vision treatment,42,43 while others do not.40,44 Rees et al45 
and Roets-Merken et al46 provide comprehensive reviews of 
the topic. To our knowledge, there are no studies investigat-
ing the effects of low vision rehabilitation in reducing anxiety 
in AMD patients. However, we do know that fewer than 25% 
of low vision rehabilitation service providers in the US offer 
any psychological treatment.47
Mixed findings notwithstanding, it must be noted that 
patients with depression may be less likely to utilize low 
vision services,40,48 and thus research that evaluates the effi-
cacy of rehabilitation to reduce depression may be hindered 
by selection bias. From a clinical standpoint, the associa-
tion between depression and underutilization of low vision 
rehabilitation suggests that service uptake may be impeded 
in patients who have severe depression, because of the moti-
vational symptoms associated with the disorder. Furthermore, 
patient characteristics (eg, personality traits) and treatment 
barriers (eg, transportation issues, financial limitations) may 
drive inconsistent study results, and perhaps suggest that a 
“one size fits all” approach to rehabilitation is not ideal.
Behavioral and self-management 
programs
To better address the psychological health of low vision 
patients, AMD-specific behavioral and self-management 
programs have been developed and tested in randomized 
controlled trials, but are not currently part of standard 
care.49–58 A core element of many of these interventions is 
teaching problem solving skills to help patients manage 
limitations brought on by vision loss. Holloway et al synthe-
sized the results of eight studies that examined the efficacy 
of problem solving based interventions to improve vision 
function, emotional distress, and depression. Overall, these 
types of intervention were found to be mildly successful in 
improving emotional distress, but there was no significant 
impact on depression. This finding should be interpreted 
cautiously because only half of the studies included in this 
review assessed depression as an outcome, the number of 
included studies was small, and many of the studies included 
participants who were not depressed. Treatment effects, 
however, were strongest in patients who were depressed at 
the start of treatment.59
Highlights of problem solving based studies are as 
follows. The “Preventing Depression in AMD” trial tested the 
efficacy of PST to prevent depression in patients with newly 
diagnosed AMD.49 PST taught patients problem solving skills 
to compensate for activity limitations during six home-based 
treatment sessions. Participants were randomized to PST or a 
usual care control group. At 2 months, 12% of PST partici-
pants were depressed compared to 23% of controls (P0.05) 
indicating that PST-treated participants had half the rate of 
depression 2 months post-treatment. PST participants were 
less likely to relinquish valued activities than control partici-
pants (23% vs 37%, respectively; P=0.04). A meditational 
analysis showed that PST prevented depression to the extent 
that activity relinquishment was minimized. These effects, 
however, were not sustained, as rates of depression were 
similar in both groups at 6 months (21% of PST participants 
vs 27% of controls). This trial demonstrated that a problem 
solving skill-based intervention can prevent depression in the 
short term but that beneficial effects decay over time.
Rees at al45 developed and tested a self-management 
program that was grounded in problem solving theory to 
address patients’ functional and emotional needs. Compared 
to controls, participants in the active treatment group did not 
show improved quality of life, emotional well-being, self-
efficacy, or improved adaptation to vision loss at 6 months. 
Results of this study, however, have limited applicability 
because the sample contained a mix of ophthalmologic 
diagnoses, and overall, was psychologically healthy at base-
line. Brody et al51,60 designed a self-management program 
that included basic information about AMD, education on 
rehabilitative strategies, and problem solving skills training. 
Compared to controls, treatment participants had significant 
improvements in mood and function at 6 weeks, and these 
effects were strongest for participants who were depressed 
at baseline. Intervention effects were sustained at 6 months. 
Birk et al61 pilot tested a group-level self-management 
intervention that included progressive muscle relaxation, 
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sharing of experiences, techniques for coping with negative 
thoughts and feelings, information regarding resources, 
and problem solving. Participants in the active treatment 
group had decreased depressive symptoms, and increased 
function scores, feelings of autonomy, and active coping. 
Although neither group demonstrated an increase in posi-
tive affect, the control group had increased negative affect. 
Wahl et al62 compared two self-management interventions 
(emotion-focused and problem-focused) in a pilot study 
of 54 participants. The emotion-focused intervention was 
based on Birk et al’s program.61 It was hypothesized that 
the emotion-focused intervention would lead to improved 
depressive symptoms and that the problem-focused interven-
tion would result in better adaptation to vision loss. Results 
showed that those in the emotion-focused intervention had 
a greater decline in depression immediately after the inter-
vention. As expected, participants in the problem-focused 
intervention demonstrated greater improvement in problem 
solving-orientation and adaptation to vision loss. None of 
the beneficial effects of either intervention were sustained 
2 months post-intervention, suggesting that longer term 
interventions, or perhaps maintenance doses, may be needed. 
Overall, studies that tested problem based interventions were 
successful in treating depressed participants, however, effects 
tend to decay over time.
Depression treatment in combination 
with low vision rehabilitation
Another strategy for treating and/or preventing depression is 
to bundle depression treatment with low vision rehabilitation. 
Girdler et al50 compared low vision rehabilitation enhanced 
with a self-management group to usual care in 77 older 
persons attending a low vision clinic (most had AMD). The 
enhanced intervention was an 8-week group program led 
by a social worker and an occupational therapist in which 
participants were taught strategies for managing vision loss. 
Participants in the enhanced intervention group had higher 
levels of activity engagement and lower rates of depression 
(17% vs 51%; P0.001). They also reported greater improve-
ments in activity participation, self-efficacy, and adjustment 
to vision loss. This study shows that an integrated low vision 
rehabilitation program that addresses psychosocial function-
ing may prevent and treat depression.
Rovner et al26 conducted a randomized trial to test the 
efficacy of a depression focused low vision rehabilitation 
intervention to prevent depression in patients with AMD 
and subclinical depressive symptoms. All participants were 
evaluated by a low vision optometrist, prescribed appropriate 
low vision devices, and were randomized to six in-home 
occupational therapy sessions or six in-home placebo ses-
sions that involved supportive therapy (ie, non-goal directed 
empathic listening). Participants in the occupational therapy 
group, in addition to being taught compensatory strategies, 
were administered a behavioral treatment for depression. 
The rate of depression at 4 months was halved in the actively 
treated group compared to the placebo group (12.6% vs 
23.4% respectively, P=0.04). Active treatment participants 
became more socially activated.
Conclusions on intervention approaches
While there are no published studies evaluating the effective-
ness of interventions designed to treat anxiety symptoms in 
AMD patients, many of the above reviewed studies show that 
behavioral interventions can treat or prevent depression in 
AMD. At this time, researchers and practitioners have a better 
understanding of the mechanisms linking vision impairment 
to depression. Also, researchers have identified therapeutic 
“ingredients” of successful interventions (for example, teaching 
problem solving skills, facilitating social engagement) to treat 
depression in AMD. Wahl63 and Schilling et al64 suggest that 
a life-span approach to adaptation to vision loss may enhance 
existing treatment. The life-span theory of control suggests that 
early on in the disease process, it is in patients’ best interests 
to enact primary control strategies such as harnessing internal 
resources (eg, effort) and utilizing external strategies (eg, use 
low vision devices) to maintain function. As vision declines 
and functional deficits increase, secondary strategies can enable 
patients to divest resources from futile goal pursuits in order 
to preserve sense of self (eg, devalue unobtainable goals and 
divert energy to realistic goals). This shift in control strategy 
may be vital to preserving psychological health.
implications for future research
The next challenge is to develop an evidence-based interven-
tion that can be implemented within existing care models, 
meets a broad range of treatment needs (eg, rehabilitative, 
psychological, social), and is streamlined, cost effective, and 
reimbursable. For instance, Margrain et al65 are currently 
investigating an integrated approach in which low vision 
patients will be screened for depression. Patients who have 
significant depressive symptoms will be randomized to a PST 
arm, a depression referral group, or a wait list control group. 
Participants in the PST group will receive a collaborative PST 
in which a trained interventionist will provide depression 
treatment and will integrate the low vision treatment plans 
into the patients’ care.
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Reimbursement policies will likely have to be modified 
to accommodate the treatment of psychiatric symptoms. 
The current system covers low vision rehabilitation only 
if there is potential to improve performance of activities 
of daily living, including self-care and home management 
skills. Maintenance therapy, which research suggests may 
be necessary to maintain benefits, are not covered.
Recommendations for eye care 
professionals
In the absence of available practice models that specifi-
cally address depression and anxiety, traditional low vision 
rehabilitation (which includes care provided by low vision 
optometrists, occupational therapists, low vision specialists, 
and other professionals with training in low vision rehabili-
tation) presents the best current treatment option to address 
these mental health problems in a rehabilitation context. 
We suggest that to improve the status quo, practitioners 
should incorporate depression and anxiety screenings into 
rehabilitation programs, so that patients whose depression 
and/or anxiety is not responding to rehabilitation can be 
identified and referred to targeted mental health care. 
Moreover, better outreach models may be needed to attract, 
in particular, depressed patients and facilitate their participa-
tion in low vision rehabilitation.
How can eye care professionals best 
address depression and anxiety in 
patients with AMD?
At the most accessible level, depression screenings, in partic-
ular, should be done in the ophthalmology clinic. Indeed, the 
preferred practice guidelines from the American Academy 
of Ophthalmology advise that:
The ophthalmologist may inquire about symptoms of 
clinical depression and, when appropriate, suggest that 
the patient seek professional advice, as depression may 
exacerbate the effects of AMD.66 
Ophthalmologists and other eye care professionals are 
uniquely positioned to identify vision-related deficits and 
related psychiatric symptoms. Discussing depression, for 
example, with patients can be awkward, uncomfortable, and 
time consuming, and few eye care professionals have specific 
training in this area. Most patients, however, do not feel 
embarrassed or uncomfortable when discussing depression.67 
Such conversations can be initiated by asking patients what 
their vision loss is preventing them from doing, how their 
independence is hindered by AMD, what they fear most about 
the loss of vision, and whether they are able to participate in 
enjoyable activities such as hobbies and social interaction. 
This line of questioning can be followed by the administration 
of a brief, standardized depression screen. The Depression 
module from the Patient Health Questionnaire-9 (PHQ-9; 
http://www.phqscreeners.com/pdfs/02_PHQ-9/English.pdf) 
is a useful tool for assessing whether depression symptoms 
or tendencies are present.68 For increased efficiency, some 
clinicians ask the first two items of the PHQ-9 as an initial 
depression screen. If the patient endorses either of these 
items, the clinician follows up with the remaining seven. This 
can be a time-saving way to screen large groups of patients 
to improve detection of undiagnosed depression.69
The same screening procedure could be used for anxiety. 
However, whereas efficient screening tools for depression 
are available to eye care professionals, anxiety screens are 
more difficult to identify, especially because anxieties among 
patients with AMD are often situation-specific. The most likely 
candidate, the Generalized Anxiety Disorder 7-item scale 
(GAD-7; http://www.phqscreeners.com/pdfs/03_GAD-7/
English.pdf),70 does not take into account the situational nature 
of AMD-related anxiety. Nevertheless, if there is reason to 
suspect a more generalized anxious response to either the diag-
nosis of AMD or related loss of vision, this scale is widely used 
and has been validated with a variety of populations. Given 
our limited understanding of anxiety in the context of AMD, 
our subsequent discussion will focus on depression.
For patients who screen positive for significant depressive 
symptoms, eye care professionals can destigmatize depres-
sion, emphasize that depression is a common and understand-
able reaction to vision loss, and explain that suffering due to 
depression can be alleviated by treatments such as medication, 
psychotherapy/counseling, or perhaps low vision rehabilita-
tion. A brief note to the patient’s primary care physician to 
alert them to the patient’s depression may lead to indicated 
mental health treatment and result in symptom reduction. 
For example, low vision patients who were referred to their 
primary care physicians, and were subsequently treated for 
depression, experienced significant reduction in symptoms.71 
Other research demonstrates that when “watchful waiting” 
procedures are implemented for older low vision patients, 
approximately one-third of those with subclinical depression 
recovered. On the other hand, 18% developed worsening, 
clinically significant depressive or anxiety disorders.72
who should be screened for depression?
Research shows that the severity of vision loss is not related 
to depression among older adults with vision impairments. 
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Perceptions of vision impairment, rather than objective 
measures such as visual acuity, are more strongly correlated 
with depression.73 In fact, patients who report functional 
vision problems (eg, difficulty navigating steps or see-
ing objects in peripheral vision) are 90% more likely be 
depressed than patients who do not report such problems, 
independent of visual acuity.73 It is therefore suggested that 
all patients with AMD be screened for psychiatric symptoms, 
regardless of AMD stage.
Integrating routine depression screening into ophthalmol-
ogy care will necessitate efficient training programs. Rees 
et al74 researched and subsequently responded to the need 
for depression training among eye care professionals. They 
interviewed 94 eye care staff (including 20 ophthalmologists) 
regarding their attitudes toward and knowledge about depres-
sion. On average, the respondents estimated that slightly more 
than half of all ophthalmology patients may be depressed, 
and most correctly identified the characteristic symptoms of 
depression. Yet, at the same time, many failed to recognize 
the physical symptoms of depression (eg, bodily pain), and 
incorrectly believed that depression could be treated with 
sleep medications or alcohol. Respondents’ confidence dis-
cussing depression and its treatment was moderate at best. 
The investigators75 then pilot tested a depression training 
program. It was delivered over the course of three 90-minute 
sessions, and covered topics such as education about depres-
sion, screening, and implementation strategies. Post-training 
interviews showed increased confidence discussing and 
screening for depression. As a result, 44% of participants 
have initiated plans to institute depression screening into 
their practices.
Conclusion
In conclusion, AMD is a prevalent eye condition among 
older adults which can have profound consequences for both 
functional and psychological well-being. There is mounting 
and consistent evidence that depression is common within 
this population, with approximately one-third reporting clini-
cally significant depressive symptomatology. The prevalence 
of depression among older adults with AMD is also higher 
than among both general populations of older adults and 
those with other common age-related medical conditions. 
While there has been less research regarding the prevalence 
and consequences of anxiety, some preliminary evidence 
indicates that older adults with AMD are also at greater risk 
for anxiety disorders than their age-peers without AMD. 
Also, it is important to remember that depression and anxiety 
often co-exist. The results of several clinical trials testing 
mental health interventions to treat depression among older 
adults with AMD have shown promising short-term results, 
especially those incorporating problem solving techniques 
and behavioral activation. Unfortunately, treatment effects do 
not appear to be maintained over time and additional studies 
are needed to determine optimal dosage and/or “booster” 
sessions needed to achieve long-term remission of depressive 
symptoms. It is clear, however, that eye care clinicians can 
no longer ignore the importance of addressing depression and 
anxiety among their patients with AMD. At the very least, 
screening for depression and anxiety needs to be incorporated 
in regular practice, especially given the availability of rela-
tively simple tools with established validity.68,70 Integrated 
models of care, meshing both low vision rehabilitation and 
mental health services, seem the most promising, and con-
tinued research is needed to demonstrate the effectiveness 
and efficacy of such models in improving both functional and 
mental health among older adults with advanced AMD.
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